University of Utah and Harvard researchers take major step toward first biological test for autism
December 1, 2010 by admin · Leave a Comment
BELMONT, MAResearchers at Harvard-affiliated McLean Hospital and the University of Utah have developed the best biologically based test for autism to date. The test was able to detect the disorder in individuals with high-functioning autism with 94 percent accuracy. The study will be published online the week of November 29th in Autism Research.
12 new epilepsy drugs usher in ‘era of abundance’
October 19, 2010 by admin · Leave a Comment
MAYWOOD, Ill. — A dozen new epilepsy drugs are giving doctors and patients more options, but making treatment decisions more complex, a Loyola epilepsy specialist reports in the journal Neurologic Clinics.
Genetic defect found to cause severe epilepsy and mental retardation
October 11, 2010 by admin · Leave a Comment
Ben-Gurion University of the Negev researcher identifies defect in the 21st amino acid that leads to progressive brain atrophy
BEER-SHEVA, Israel, October 12, 2010 A research team at Ben-Gurion University of the Negev and Soroka University Medical Center in Beer-Sheva, Israel has detected a genetic mutation resulting in a progressive disease of severe mental retardation and epilepsy beginning at infancy. The research was just published in the American Journal of Human Genetics.
Scripps research study opens the door to new class of drugs for epileptic seizures
July 27, 2010 by admin · Leave a Comment
LA JOLLA, CA July 28, 2010 For Immediate Release A chemical compound that boosts the action of a molecule normally produced in the brain may provide the starting point for a new line of therapies for the treatment of epileptic seizures, according to a new study by scientists at The Scripps Research Institute.
FDA accepts historical controls for epilepsy monotherapy studies
July 19, 2010 by admin · Leave a Comment
Major turning point in antiepileptic drug testing and development
New York University researchers revealed that data from previously completed withdrawal to monotherapy studies for antiepileptic drugs (AEDs) provide a valid control for future studies, obviating the need for placebo/pseudo-placebo trials to demonstrate the efficacy of these drugs as monotherapy. Results of this study are now available online in Epilepsia, a journal published by Wiley-Blackwell on behalf of the International League Against Epilepsy.
